Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cyclerion Therapeutics (CYCN) Operating Leases (2019 - 2021)

Cyclerion Therapeutics has reported Operating Leases over the past 3 years, most recently at $38.1 million for Q1 2021.

  • Quarterly results put Operating Leases at $38.1 million for Q1 2021, down 19.1% from a year ago — trailing twelve months through Mar 2021 was $38.1 million (down 19.1% YoY), and the annual figure for FY2020 was $38.9 million, down 44.78%.
  • Operating Leases for Q1 2021 was $38.1 million at Cyclerion Therapeutics, down from $38.9 million in the prior quarter.
  • Over the last five years, Operating Leases for CYCN hit a ceiling of $72.4 million in Q2 2019 and a floor of $38.1 million in Q1 2021.
  • Median Operating Leases over the past 3 years was $46.7 million (2020), compared with a mean of $53.1 million.
  • Biggest five-year swings in Operating Leases: tumbled 44.78% in 2020 and later fell 19.1% in 2021.
  • Cyclerion Therapeutics' Operating Leases stood at $70.5 million in 2019, then tumbled by 44.78% to $38.9 million in 2020, then dropped by 2.22% to $38.1 million in 2021.
  • The last three reported values for Operating Leases were $38.1 million (Q1 2021), $38.9 million (Q4 2020), and $39.8 million (Q3 2020) per Business Quant data.